Evidence map›Paper›PMID 31624769›Full record

ArticleWorld journal of clinical cases2019

Advanced primary amelanotic malignant melanoma of the esophagus: A case report.

Ruo-Xi Zhang, Ya-Ying Li, Chang-Jie Liu, Wei-Na Wang, Ying Cao, Yong-Hua Bai, Ti-Jiang Zhang

Open access · diamondAbstract readCase Reports
In one paragraph

Article in World journal of clinical cases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Unveiling a Rare Cause of Dysphagia.GE Portuguese journal of gastroenterology · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ruo-Xi ZhangDepartment of Radiology, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou Province, China.
Ya-Ying LiDepartment of Radiology, Guizhou Provincial People's Hospital, Guiyang 550002, Guizhou Province, China.
Chang-Jie LiuDepartment of Radiology, Guizhou Provincial People's Hospital, Guiyang 550002, Guizhou Province, China.
Wei-Na WangDepartment of Radiology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
Ying CaoDepartment of Pathology, Guizhou Provincial People's Hospital, Guiyang 550002, Guizhou Province, China.
Yong-Hua BaiDepartment of Pathology, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou Province, China.
Ti-Jiang ZhangDepartment of Radiology, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou Province, China. tijzhang@163.com.
West China Hospital of Sichuan University · CNZunyi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary malignant melanoma of the esophagus accounts for 0.1%-0.2% of all esophageal malignancies, including melanotic and amelanotic melanomas. Primary amelanotic malignant melanoma of the esophagus is extremely rare, and only about 20 cases have been published in the literature to date. Most primary malignant melanomas of the esophagus are diagnosed following development of metastatic lesions and thus have a very poor prognosis. The median survival duration of patients with metastatic melanoma has been reported to be 6.2 mo. CASE SUMMARY: A 49-year-old woman was referred to our hospital with a diagnosis of esophageal cancer. Endoscopy, biopsy, imaging evaluation, and physical examination at our hospital indicated a diagnosis of advanced primary amelanotic malignant melanoma of the esophagus. Immunohistochemical staining confirmed melanoma. Nuclear medicine examination revealed a left iliac bone metastatic lesion. After discharge, the patient self-administered apatinib for 3 mo, followed by oral treatment with Chinese medicines (also self-administered) for 2 mo. No treatments had been taken since then. The patient has survived with no growth out to the most recent follow-up (24 mo post diagnosis), and she always presented with a positive attitude about her condition during this period.

conclusionSurvival following metastatic melanoma might be related to the pharmaceutical and Chinese medicine treatment and the patient's positive attitude.

Indexed as

Amelanotic malignant melanomaCase reportEmotionEsophagusImmunePsychological intervention

Identifiers

PMID31624769
PMCPMC6795737
OpenAlexW2975523171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.